Pharmathen licenses technology to Recordati

Pharmathen grants exclusive rights to Recordati S.p.A for its innovative drug delivery platform.

Pharmathen S.A. announces an agreement with Recordati, regarding the licensing of an innovative drug delivery system developed in Pharmathen’s laboratories. The technology results in improved formulations soon to be submitted for Marketing authorizations to the European Authorities

This new agreement with Recordati, signals a new era for Pharmathen. The company, holding a dominant position in the global generic market, considers this latest partnership as the first step towards its dynamic entrance in the field of innovative products. Pharmathen currently has in its pipeline 6 innovative projects and/or life cycle management opportunities and is already in discussions with major multinational companies.